Home /
Insights & Resources
Insights & Resources
Start exploring insights from across the industries we serve, featuring the latest industry trends, compliance alerts, tax and accounting news and much more.
- Alternative Investments
- Banking
- Blockchain & Digital Assets
- Construction
- Consumer Products
- Energy Transition
- Financial Services
- Food & Beverage
- General Business
- Government
- Health Care
- Higher Education
- Hospitality & Entertainment
- Industrial Products
- Insurance
- Life Sciences
- Not-for-Profit
- Oil & Gas
- Oilfield Services
- Real Estate
- Renewable Fuels
- Technology
- Transportation & Logistics
- Accounting Advisory
- Artificial Intelligence
- Asset Management Consulting
- Asset Tracing
- Cybersecurity
- Data Privacy
- Digital Transformation
- Energy Compliance
- Executive & Leadership Coaching
- Family Law
- Forensics & Litigation
- Government Consulting
- Health Care Valuation
- IT Advisory
- Risk Advisory
- Sustainability Consulting
- Transaction Advisory
- Trust & Estate
- Valuation
Cash flow, ownership and exit planning shape entity selection. Learn how to choose the right structure for long-term business success.
Discover what the NAM Q2 Outlook Survey reveals about manufacturing costs, AI investment and business planning. Watch now.
The SBIR and STTR reauthorization brings larger awards, stricter eligibility and more competition for life sciences companies seeking federal funding.
Manufacturers often overlook sales and use tax exposure. Learn where audits focus and how to reduce risk and recover overpayments.
Learn why Texas is a leading life sciences hub, from workforce to funding. Discover what’s driving growth and what it means for companies.
Kurtis Dixon and Marvin Ferguson explain the tax benefits of AI in manufacturing, from R&D credits to expensing strategies.
Discover strategies to tackle tariffs and boost business resilience through smarter sourcing, planning and risk from Kurtis Dixon and Marvin Ferguson.
Texas life sciences in 2025 saw concentrated capital, declining innovation output and earlier‑stage clinical shifts shaping the ecosystem.
Texas life sciences saw record capital in Q4 2025, even as innovation, early-stage funding and late-phase clinical trials continued to decline.
Kurtis Dixon and Marvin Ferguson break down how the OBBBA reshapes bonus depreciation, R&D costs and strategies for year-end tax planning.
Weaver created a durable environmental reporting framework for a global supplier: greenhouse gas tracking, audit readiness and sustainability.
Maximize year-end tax benefits with Kurtis Dixon and Marvin Ferguson, as they explore bonus depreciation, equipment timing and deductions.